Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8049)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jul 28, 2015 (publication date) through Apr 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Hilgenfeldt EG, Schlachterman A, Firpi RJ. Hepatitis C: Treatment of difficult to treat patients. World J Hepatol 2015; 7(15): 1953-1963 [PMID: 26244069 DOI: 10.4254/wjh.v7.i15.1953] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v7/i15/1953.htm |
| Number | Citing Articles |
| 1 |
Hailong Wang, Xiu Xin, Mingzhen Wang, Lingling Han, Jiadai Li, Yao Hao, Congyi Zheng, Chao Shen. Myxovirus resistance protein A inhibits hepatitis C virus replication through JAK-STAT pathway activation. Archives of Virology 2018; 163(6): 1429 doi: 10.1007/s00705-018-3748-3
|
| 2 |
Ioana-Alina Harja-Alexa, Luca Catalina Mihaela, Carmen Doina Manciuc, Andrei Vata, Aida Badescu, Mihnea-Eudoxiu Hurmuzache, Alexandra Mirela Ciocan, Ioana Maria Hunea, Luminita-Smaranda Iancu. Extended panel of biomarkers for long term monitoring of effectiveness of 3 direct antiviral regimen in HCV genotype 1b infection: results from a Romanian infectious disease hospital. Revista Romana de Medicina de Laborator 2021; 29(1): 93 doi: 10.2478/rrlm-2020-0040
|
| 3 |
Kittirat Glab-ampai, Monrat Chulanetra, Aijaz Ahmad Malik, Thanate Juntadech, Jeeraphong Thanongsaksrikul, Potjanee Srimanote, Kanyarat Thueng-in, Nitat Sookrung, Pongsri Tongtawe, Wanpen Chaicumpa. Human single chain-transbodies that bound to domain-I of non-structural protein 5A (NS5A) of hepatitis C virus. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-14886-9
|
| 4 |
Nikhil Pathak, Mei-Ling Lai, Wen-Yu Chen, Betty-Wu Hsieh, Guann-Yi Yu, Jinn-Moon Yang. Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV infection. BMC Bioinformatics 2017; 18(S16) doi: 10.1186/s12859-017-1957-5
|
| 5 |
Jason D. Graci, Stephen P. Jung, John Pichardo, Frederick Lahser, Xiao Tong, Zhengxian Gu, Joseph M. Colacino. PTC725, an NS4B-Targeting Compound, Inhibits a Hepatitis C Virus Genotype 3 Replicon, as Predicted by Genome Sequence Analysis and Determined Experimentally. Antimicrobial Agents and Chemotherapy 2016; 60(12): 7060 doi: 10.1128/AAC.01272-16
|
| 6 |
Islam El-Garawani, Sobhy Hassab El-Nabi, Marwa Gadallah, Eman Abdelsameea. Association between IFN-λ 3 Gene Polymorphisms and Outcome of Treatment with Direct Acting Antivirals in Chronic HCV-Infected Egyptian Patients. Immunological Investigations 2021; 50(1): 12 doi: 10.1080/08820139.2020.1722158
|
| 7 |
Sowmya Pattabhi, Courtney R. Wilkins, Ran Dong, Megan L. Knoll, Jeffrey Posakony, Shari Kaiser, Chad E. Mire, Myra L. Wang, Renee C. Ireton, Thomas W. Geisbert, Kristin M. Bedard, Shawn P. Iadonato, Yueh-Ming Loo, Michael Gale, B. Williams. Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway. Journal of Virology 2016; 90(5): 2372 doi: 10.1128/JVI.02202-15
|
| 8 |
Mohammed Lak, Mohammed Mohammed, Muhsin Mohammed, Ali Ahmad. HARVONI VERSUS 3D REGIMENS OUTCOMES AMONG HCV INFECTED PATIENTS VISITED KURDISTAN CENTRE FOR GASTROENTEROLOGY AND HEPATOLOGY (KCGH). JOURNAL OF SULAIMANI MEDICAL COLLEGE 2022; 12(1): 1 doi: 10.17656/jsmc.10338
|
| 9 |
Mark Nelson, Rafael Rubio, Adriano Lazzarin, Svetlana Romanova, Annie Luetkemeyer, Brian Conway, Jean-Michel Molina, Dong Xu, Subasree Srinivasan, Simon Portsmouth. Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients. Journal of Interferon & Cytokine Research 2017; 37(3): 103 doi: 10.1089/jir.2016.0082
|
| 10 |
Florian Douam, Qiang Ding, Alexander Ploss. Recent advances in understanding hepatitis C. F1000Research 2016; 5: 131 doi: 10.12688/f1000research.7354.1
|
| 11 |
Joydeep Chakraborty, Eric Hilgenfeldt, Roniel Cabrera. Precision Molecular Pathology of Liver Cancer. Molecular Pathology Library 2018; : 175 doi: 10.1007/978-3-319-68082-8_10
|
| 12 |
Mingzhen Wang, Yu Wang, Yuehong Liu, Hailong Wang, Xiu Xin, Jiadai Li, Yao Hao, Lingling Han, Fang Yu, Congyi Zheng, Chao Shen, Chiaho Shih. SPSB2 inhibits hepatitis C virus replication by targeting NS5A for ubiquitination and degradation. PLOS ONE 2019; 14(7): e0219989 doi: 10.1371/journal.pone.0219989
|
| 13 |
Nicholas A. Meanwell, Ramkumar Rajamani, Paul M. Scola,
Li-Qiang Sun. HCV: The Journey from Discovery to a Cure. Topics in Medicinal Chemistry 2019; 31: 317 doi: 10.1007/7355_2018_58
|
| 14 |
Cloé Comarmond, Patrice Cacoub, David Saadoun. Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals. Therapeutic Advances in Gastroenterology 2020; 13: 175628482094261 doi: 10.1177/1756284820942617
|
| 15 |
Eli Zuckerman, Julio A. Gutierrez, Douglas E. Dylla, Victor de Ledinghen, Andrew J. Muir, Michael Gschwantler, Massimo Puoti, Florin Caruntu, Jihad Slim, Frederik Nevens, Samuel Sigal, Stanley Cohen, Linda M. Fredrick, Ana Gabriela Pires dos Santos, Lino Rodrigues, John F. Dillon. Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology 2020; 18(11): 2544 doi: 10.1016/j.cgh.2020.06.044
|
| 16 |
Bettina Zippel-Schultz, Michael Specka, Konrad Cimander, Thomas Eschenhagen, Jörg Gölz, Markus Maryschok, Manfred Nowak, Thomas Poehlke, Heino Stöver, Thomas M. Helms, Norbert Scherbaum. Outcomes of Patients in Long-Term Opioid Maintenance Treatment. Substance Use & Misuse 2016; 51(11): 1493 doi: 10.1080/10826084.2016.1188946
|
| 17 |
Jingbo Yang. Hepatitis C Risk Prediction Based on Adaboost. Highlights in Science, Engineering and Technology 2023; 54: 413 doi: 10.54097/hset.v54i.9803
|
| 18 |
Ellen Childs, Sabrina A. Assoumou, Katie B. Biello, Dea L. Biancarelli, Mari-Lynn Drainoni, Alberto Edeza, Peter Salhaney, Matthew J. Mimiaga, Angela R. Bazzi. Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs. Harm Reduction Journal 2019; 16(1) doi: 10.1186/s12954-019-0286-6
|
| 19 |
Hu Li, Jia-Li Tan, Jian-Rui Li, Nan-Nan Liu, Jin-Hua Chen, Xiao-Qin Lv, Li-li Zou, Biao Dong, Zong-Gen Peng, Jian-Dong Jiang. A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens. Biomedicine & Pharmacotherapy 2019; 116: 108976 doi: 10.1016/j.biopha.2019.108976
|